Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRILIPIX vs ATROMID-S
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
TRILIPIX (fenofibric acid) is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase, and reduces production of apoprotein C-III.
Inhibits hepatic triglyceride synthesis and increases lipoprotein lipase activity, leading to reduced VLDL and triglycerides.
Adjunctive therapy to diet for severe hypertriglyceridemia (Fredrickson types IV and V hyperlipidemia),Primary hypercholesterolemia or mixed dyslipidemia (Fredrickson types IIa and IIb)
Type III hyperlipoproteinemia,Hypertriglyceridemia (Fredrickson types IV and V) not responsive to diet
135 mg orally once daily, not to exceed 135 mg/day.
500 mg to 1 g orally twice daily. Maximum dose 2 g/day.
Terminal elimination half-life of fenofibric acid is approximately 20 hours (range 10-35 hours), allowing once-daily dosing.
Terminal elimination half-life is 6-8 hours in patients with normal renal function; may be prolonged to 12-24 hours in renal impairment.
Fenofibric acid is primarily metabolized via glucuronidation. It is not metabolized by cytochrome P450 (CYP) enzymes.
Hepatic via glucuronidation and oxidation; major metabolite is clofibric acid.
Primarily renal excretion as glucuronide conjugate and unchanged drug; ~60% of dose excreted in urine as fenofibric acid and its glucuronide, ~25% in feces.
Primarily renal excretion as glucuronide conjugates; approximately 60-70% of the dose is excreted in urine, 20-30% in feces via biliary elimination.
Fenofibric acid is highly bound to plasma albumin (>99%).
>95% bound to plasma proteins, primarily albumin.
Apparent volume of distribution (Vd/F) is approximately 0.9 L/kg, indicating distribution into extracellular fluid.
0.11-0.14 L/kg; low Vd indicates limited extravascular distribution, consistent with high protein binding.
Absolute bioavailability of fenofibric acid from TRILIPIX is not determined; relative bioavailability compared to micronized fenofibrate is approximately 100% after oral administration.
Oral: approximately 60-70% due to first-pass metabolism; administered as clofibrate (prodrug) which is hydrolyzed to active clofibric acid.
Contraindicated in severe renal impairment (e GFR <30 m L/min/1.73 m²). For mild to moderate impairment (e GFR 30-59 m L/min/1.73 m²), maximum dose is 67 mg daily.
GFR 30-59 m L/min: 500 mg twice daily. GFR 15-29 m L/min: 250 mg twice daily. GFR <15 m L/min: avoid use.
Contraindicated in Child-Pugh Class B and C hepatic impairment. No dose adjustment specified for Child-Pugh Class A; use with caution.
Child-Pugh Class B or C: avoid use or reduce dose by at least 50%; not recommended in severe hepatic impairment.
Safety and efficacy not established in pediatric patients.
Not recommended; safety and efficacy not established in pediatric patients.
No specific dose adjustment recommended; select dose cautiously due to age-related renal function decline.
Start at lower end of dosing range (500 mg twice daily). Monitor renal function; adjust dose based on GFR.
There is no FDA-required black box warning for TRILIPIX.
None
Risk of myopathy/rhabdomyolysis, especially in patients with renal impairment or those taking statins,Elevations in serum transaminases, possibly leading to cholelithiasis,Hepatocellular and obstructive jaundice have been reported,Monitor renal function prior to and during therapy,Not recommended in patients with severe renal impairment (e GFR <30 m L/min/1.73 m²)
Hepatotoxicity,Cholelithiasis,Renal impairment dose adjustment,Rhabdomyolysis risk with statins,Malignancy risk (hepatic, GI)
Severe renal impairment (e GFR <30 m L/min/1.73 m²),Active liver disease (including unexplained persistent liver function abnormalities),Pre-existing gallbladder disease,Known hypersensitivity to fenofibric acid, fenofibrate, or any component of the formulation
Hypersensitivity to clofibrate,Active liver disease,Severe renal dysfunction,Primary biliary cirrhosis,Pregnancy
Avoid high-fat meals during administration as they can alter fenofibric acid absorption. Avoid grapefruit juice as it may increase drug exposure. Alcohol consumption should be limited (no more than 1 drink per day for women, 2 for men) due to potential hepatotoxicity and worsening of hypertriglyceridemia.
High-fat meals may reduce absorption; consistent timing of administration with food is recommended. Grapefruit juice may increase drug levels; avoid excessive intake. Alcohol may exacerbate hepatotoxicity.
Pregnancy category C. First trimester: No adequate studies in humans; animal studies show fetal toxicity at high doses. Second and third trimesters: Use only if benefit outweighs risk; may cause fetal harm due to maternal hypertriglyceridemia or drug effects.
FDA Pregnancy Category C. First trimester: Potential for teratogenicity based on animal studies showing skeletal and visceral anomalies. Human data limited; use only if benefit outweighs risk. Second and third trimesters: May cause fetal harm due to placental transfer and potential for reduced fetal growth.
Not recommended. M/P ratio unknown; fenofibric acid is excreted in rat milk; potential for serious adverse reactions in nursing infants.
Excreted into breast milk in low amounts; M/P ratio not established. Due to potential for serious adverse effects in infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
No established dosing adjustments; pharmacokinetics in pregnancy unknown. Use lowest effective dose if necessary; avoid in third trimester unless essential.
No specific dosing adjustments recommended due to lack of data. However, pharmacokinetic changes in pregnancy (increased volume of distribution, altered metabolism) may necessitate careful monitoring and empiric dose adjustments based on clinical response and adverse effects.
TRILIPIX (fenofibric acid) is a fibric acid derivative used as an adjunct to diet for severe hypertriglyceridemia. Monitor renal function prior to initiation and periodically; dose reduction required for e GFR 30-59 m L/min/1.73m². Contraindicated in severe renal impairment (e GR <30) and active liver disease. May increase serum creatinine; typically reversible. Co-administration with statins increases risk of myopathy/rhabdomyolysis; avoid in patients with predisposing factors. Not recommended for primary prevention of coronary heart disease.
ATROMID-S (clofibrate) is a fibric acid derivative primarily indicated for hyperlipidemia but its use is now limited due to increased non-cardiovascular mortality and cholelithiasis risk. Monitor liver function and prothrombin time (potentiates warfarin). Not first-line; consider statins or fibrates like fenofibrate.
Take TRILIPIX with or without food, but avoid taking with a high-fat meal as it may increase absorption variability.,Report unexplained muscle pain, tenderness, or weakness, especially if accompanied by fever or malaise.,Inform your healthcare provider if you have kidney disease, liver disease, or a history of gallbladder problems.,Do not take this medication if you are pregnant or breastfeeding without consulting your doctor.,Alcohol consumption should be minimized or avoided as it can increase triglyceride levels and liver stress.
Take with meals to reduce gastrointestinal upset.,Report unexplained muscle pain, tenderness, or weakness; may indicate myopathy.,Avoid alcohol as it may increase liver enzyme elevations.,Notify your doctor if you develop gallstones symptoms (e.g., right upper abdominal pain, nausea).,Use effective contraception as clofibrate may cause fetal harm.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TRILIPIX vs ATROMID-S, answered by our medical review team.
TRILIPIX is a Fibrate Antilipemic that works by TRILIPIX (fenofibric acid) is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase, and reduces production of apoprotein C-III.. ATROMID-S is a Antilipemic Agent that works by Inhibits hepatic triglyceride synthesis and increases lipoprotein lipase activity, leading to reduced VLDL and triglycerides.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRILIPIX and ATROMID-S depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRILIPIX is: 135 mg orally once daily, not to exceed 135 mg/day.. The standard adult dose of ATROMID-S is: 500 mg to 1 g orally twice daily. Maximum dose 2 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRILIPIX and ATROMID-S in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRILIPIX is classified as Category C. Pregnancy category C. First trimester: No adequate studies in humans; animal studies show fetal toxicity at high doses. Second and third trimesters: Use only if benefit outweighs r. ATROMID-S is classified as Category C. FDA Pregnancy Category C. First trimester: Potential for teratogenicity based on animal studies showing skeletal and visceral anomalies. Human data limited; use only if benefit out. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.